Anti‐COVID‐19 measurements for hidradenitis suppurativa patients

The reported incidence of COVID‐19 among cohorts of patients with inflammatory bowel and skin diseases under treatment with biologicals is low. Treatment may further modify disease severity as some biological modifiers, such as anakinra, are also proposed for the management of COVID‐19 patients pote...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Exp Dermatol
Päätekijät: Giamarellos‐Bourboulis, Evangelos J., Bettoli, Vincenzo, Jemec, Gregor B. E., del Marmol, Veronique, Marzano, Angelo V., Prens, Errol P., Tzellos, Thrasyvoulos, Zouboulis, Christos C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2021
Aiheet:
10th European Hidradenitis Suppurativa (EHSF) e.V. Conference
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8207032/
https://ncbi.nlm.nih.gov/pubmed/34085330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/exd.14339
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia